What is HC Wainwright’s Forecast for Myomo Q1 Earnings?

Myomo, Inc. (NYSEAMERICAN:MYO) – Analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Myomo in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings per share of ($0.09) for the quarter, up from their previous forecast of ($0.11). HC Wainwright has a “Buy” rating and a $9.50 price objective on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.13) EPS and FY2027 earnings at $0.20 EPS.

MYO has been the subject of several other research reports. Craig Hallum increased their price objective on shares of Myomo from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, March 11th. Alliance Global Partners reaffirmed a “buy” rating on shares of Myomo in a report on Tuesday, March 11th. Finally, Ascendiant Capital Markets boosted their price objective on shares of Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Monday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Myomo presently has an average rating of “Buy” and an average price target of $9.75.

Myomo Trading Up 4.8 %

Shares of NYSEAMERICAN:MYO opened at $5.44 on Monday. The stock has a market cap of $164.56 million, a P/E ratio of -23.65 and a beta of 1.68. Myomo has a one year low of $2.51 and a one year high of $7.17.

Insider Buying and Selling at Myomo

In other Myomo news, insider Micah Mitchell sold 48,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $5.16, for a total transaction of $247,680.00. Following the transaction, the insider now owns 140,572 shares of the company’s stock, valued at $725,351.52. This trade represents a 25.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas F. Kirk purchased 7,400 shares of the stock in a transaction dated Thursday, March 13th. The stock was purchased at an average price of $5.00 per share, with a total value of $37,000.00. Following the completion of the acquisition, the director now directly owns 255,933 shares in the company, valued at approximately $1,279,665. The trade was a 2.98 % increase in their position. The disclosure for this purchase can be found here. 4.54% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Myomo

Several large investors have recently added to or reduced their stakes in the company. Barclays PLC acquired a new stake in shares of Myomo during the 3rd quarter worth approximately $36,000. BNP Paribas Financial Markets bought a new position in Myomo during the 4th quarter worth $64,000. Walleye Capital LLC acquired a new stake in Myomo in the fourth quarter worth $66,000. Squarepoint Ops LLC acquired a new stake in Myomo in the fourth quarter worth $74,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in Myomo in the fourth quarter valued at $95,000. 44.99% of the stock is currently owned by institutional investors.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.